Literature DB >> 12836789

Evaluation of written prescription information provided in community pharmacies: a study in eight states.

Bonnie L Svarstad1, Dara C Bultman, Jeanine K Mount, Ellen R Tabak.   

Abstract

OBJECTIVES: To develop three tools for assessing the quality of written information provided with new prescriptions in community pharmacies and to identify pharmacy, pharmacist, and patient characteristics associated with the dissemination and quality of that information.
DESIGN: Observational study. Regression techniques were used to analyze the influence of pharmacy, pharmacist, and shopper (acting as patient) characteristics on outcome measures. PARTICIPANTS: Trained shoppers (acting as patients) visited 306 randomly selected pharmacies in 8 states. Each shopper presented three prescriptions, answered questions according to a standard scenario, accepted the information offered, and paid for the prescriptions. MAIN OUTCOME MEASURES: Percentage of shoppers receiving any written information; quality of written information as judged by an expert panel using explicit criteria.
RESULTS: Shoppers received an information leaflet with 87% of the 918 prescriptions dispensed. Although most leaflets provided unbiased information, leaflet length and quality of information varied greatly. A majority of leaflets did not include adequate information about contraindications, precautions, and how to avoid harm. Shoppers were more likely to receive leaflets in chain pharmacies and pharmacies with more staff. Information quality also was higher in chain pharmacies. Shopper and pharmacist demographic characteristics were unrelated to the level or quality of written information after controlling for other factors.
CONCLUSION: The provision of patient leaflets is becoming a routine practice in the states studied. However, most leaflets do not meet quality criteria. It is important for pharmacists to become familiar with criteria for evaluating these leaflets and to take necessary action to improve their quality.

Entities:  

Mesh:

Year:  2003        PMID: 12836789     DOI: 10.1331/154434503321831102

Source DB:  PubMed          Journal:  J Am Pharm Assoc (2003)        ISSN: 1086-5802


  8 in total

1.  A profile of concurrent alcohol and alcohol-interactive prescription drug use in the US population.

Authors:  Jessica J Jalbert; Brian J Quilliam; Kate L Lapane
Journal:  J Gen Intern Med       Date:  2008-09       Impact factor: 5.128

2.  Low literacy impairs comprehension of prescription drug warning labels.

Authors:  Terry C Davis; Michael S Wolf; Pat F Bass; Mark Middlebrooks; Estela Kennen; David W Baker; Charles L Bennett; Ramon Durazo-Arvizu; Anna Bocchini; Stephanie Savory; Ruth M Parker
Journal:  J Gen Intern Med       Date:  2006-08       Impact factor: 5.128

3.  Exploring pharmacist-customer communication: the established blood pressure measurement episode.

Authors:  Afonso Neves Cavaco; João P Romano
Journal:  Pharm World Sci       Date:  2010-07-21

4.  Access to multilingual medication instructions at New York City pharmacies.

Authors:  Linda Weiss; Francesca Gany; Peri Rosenfeld; Olveen Carrasquillo; Iman Sharif; Elana Behar; Emily Ambizas; Priti Patel; Lauren Schwartz; Robert Mangione
Journal:  J Urban Health       Date:  2007-11       Impact factor: 3.671

5.  The usefulness and scientific accuracy of private sector Arabic language patient drug information leaflets.

Authors:  Sana R Sukkari; Abdullah S Al Humaidan; Larry D Sasich
Journal:  Saudi Pharm J       Date:  2012-01-28       Impact factor: 4.330

Review 6.  Written information about individual medicines for consumers.

Authors:  Donald Nicolson; Peter Knapp; D K Theo Raynor; Pat Spoor
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

7.  Medicine information leaflets for non-steroidal anti-inflammatory drugs in Thailand.

Authors:  Pacharaporn Phueanpinit; Juraporn Pongwecharak; Janet Krska; Narumol Jarernsiripornkul
Journal:  Int J Clin Pharm       Date:  2015-11-18

8.  Biennial Analysis of Medication Guide Length and Estimated Readability for New Molecular Entity Drugs, 2011-2017.

Authors:  Paul R Jones; Elisabeth J Walther; Andrew Nguyen; Jonas Santiago; Bryon M Pearsall
Journal:  Ther Innov Regul Sci       Date:  2021-05-10       Impact factor: 1.337

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.